Liminal BioSciences Inc.

Liminal BioSciences Inc.

$8.5
0.01 (0.12%)
NASDAQ Global Market
USD, CA
Biotechnology

LMNL Price Chart

Basic
Market Cap$27.62M
Price$8.5
52 Week Range3.1-8.5
Beta29.34
Margins
Gross Profit Margin100.00%
Operating Profit Margin-8223.19%
Net Profit Margin-7210.97%
Valuation (TTM)
P/E Ratio-1.31
Price to Sales Ratio98.71
Price to Book Ratio1.04
PEG Ratio-0.01

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

251

IPO Date

2009-12-18T00:00:00.000Z

Description

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Phone

14507810115

Address

440 Armand-Frappier Boulevard, Laval, QC, H7V 4B4, CA

CIK

0001351172